pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
Fulcrum Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker FULC. Primary therapeutic focus areas include Facioscapulohumeral Muscular Dystrophy (FSHD), Facioscapulohumer
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
Quick answer
Fulcrum Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker FULC. Primary therapeutic focus areas include Facioscapulohumeral Muscular Dystrophy (FSHD), Facioscapulohumeral Muscular Dystrophy 1 (FSHD1), Sickle Cell Disease, Campylobacter Infection, Facioscapulohumeral Muscular Dystrophy 1. NovaPharmaNews links 12 clinical program(s), 0 drug profile(s), and 11 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (6), phase 3 (3), phase 1 (3).
Company snapshot
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Community Guidelines: https://bit.ly/3t2xeR9
- 12 active pipeline program(s) linked via ClinicalTrials.gov.
- 11 US patent(s) indexed to this assignee profile.
- 12 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Fulcrum Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
- approval
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
- approval
Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures
- trial_data
Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug
- trial_data
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
- approval
Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
Recent coverage
Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
This week, the biotech sector saw a wave of regulatory and business development activity: PHG and KMDA won FDA approvals, FULC halted its pociredir program, RMD closed the Noctrix acquisition, and NVS posted positive data in IgAN. We break down what each event means for pharma teams and investors.
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.
Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures
A ten-year-old Cambridge-based biotech company is actively seeking a merger or acquisition. This move comes as public markets have shown volatility, impacting biotech valuations.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 2
Momentum
Proprietary activity score for Fulcrum Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Fulcrum Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Fulcrum Therapeutics?
-
Is Fulcrum Therapeutics publicly traded?
-
What drugs does Fulcrum Therapeutics develop or market?
-
What are the latest developments for Fulcrum Therapeutics?
-
What therapeutic areas does Fulcrum Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.